Clinical trial NCT01131676: BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).
Official title: A Phase III, Multicentre, International, Randomised, Parallel Group, Double Blind Cardiovascular Safety Study of BI 10773 (10 mg and 25 mg Administered Orally Once Daily) Compared to Usual Care in Type 2 Diabetes Mellitus Patients With Increased Cardiovascular Risk
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
Collaborators: name: Eli Lilly and Company
First posted: 2010-05-27
Enrollment: 7064
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.


Eligibility criteria: Inclusion criteria:

1. Diagnosis of type 2 diabetes mellitus prior to informed consent
2. Male or female patients on diet and exercise regimen who are drug naive or pre treated with any background therapy. Antidiabetic therapy has to be unchanged for 12 weeks prior to randomization.
3. Glycosylated haemoglobin (HbA1c) of \>= 7.0% and \<=10% for patients on background therapy or HbA1c \>= 7.0% and \<= 9.0% for drug naive patients
4. Age \>= 18 years
5. Body Mass index \<= 45 at Visit 1
6. Signed and dated informed consent
7. High cardiovascular risk

Exclusion criteria:

1. Uncontrolled hyperglycaemia with a glucose level \>240 mg/dl (\>13.3 mmol/L) after an overnight fast during placebo run-in and confirmed by a second measurement (not on the same day)
2. Indication of liver disease, defined by serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase ALT or alkaline phosphatase above 3 x upper limit of normal (ULN) as determined at screening and/or run in.
3. Planned cardiac surgery or angioplasty within 3 months
4. Impaired renal function, defined as Glomerular Filtration Rate \<30 ml/min (severe renal impairment, Modification of Diet in Renal Disease formula) during screening or run in.
5. Bariatric surgery within the past two years and other gastrointestinal surgeries that induce chronic malabsorption
6. Blood dyscrasias or any disorders causing haemolysis or unstable Red Blood Cell (e.g. malaria, babesiosis, haemolytic anemia)
7. Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years
8. Contraindications to background therapy according to the local label
9. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to informed consent or any other treatment at the time of screening (i.e. surgery, aggressive diet regimen, etc.) leading to unstable body weight
10. Current treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent or any other uncontrolled endocrine disorder except type 2 diabetes mellitus
11. Pre-menopausal women (last menstruation \<+ 1 year prior to informed consent) who:

    * are nursing or pregnant or
    * are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable or injectable contraceptives, sexual abstinence, double barrier method and vasectomised partner
12. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake
13. Participation in another trial with an investigational drug within 30 days prior to informed consent
14. Any other clinical condition that would jeopardize patients safety while participating in this clinical trial
15. Acute coronary syndrome, stroke or TIA within 2 months prior to informed consent

Primary outcomes:
measure: Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke.
timeFrame: From randomisation to individual end of observation, up to 4.6 years
Secondary outcomes:
measure: Percentage of Participants With the Composite of All Events Adjudicated (4-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), Non-fatal Stroke and Hospitalization for Unstable Angina Pectoris
timeFrame: From randomisation to individual end of observation, up to 4.6 years
measure: Percentage of Participants With Silent MI
timeFrame: From randomisation to individual end of observation, up to 4.6 years
measure: Percentage of Participants With Heart Failure Requiring Hospitalisation (Adjudicated)
timeFrame: From randomisation to individual end of observation, up to 4.6 years
measure: Percentage of Participants With New Onset Albuminuria
timeFrame: From randomisation to individual end of observation, up to 4.6 years
measure: Percentage of Participants With New Onset Macroalbuminuria
timeFrame: From randomisation to individual end of observation, up to 4.6 years
measure: Percentage of Participants With the Composite Microvascular Outcome
timeFrame: From randomisation to individual end of observation, up to 4.6 years
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: 1245.25.10043 Boehringer Ingelheim Investigational Site
state: Alabama
city: Birmingham
country: United States
facility: 1245.25.10121 Boehringer Ingelheim Investigational Site
state: Alabama
city: Huntsville
country: United States
facility: 1245.25.10037 Boehringer Ingelheim Investigational Site
state: Alabama
city: Mobile
country: United States
facility: 1245.25.10124 Boehringer Ingelheim Investigational Site
state: Alabama
city: Little Rock
country: United States
facility: 1245.25.10015 Boehringer Ingelheim Investigational Site
state: Alaska
city: Gilbert
country: United States
facility: 1245.25.10056 Boehringer Ingelheim Investigational Site
state: Arizona
city: Peoria
country: United States
facility: 1245.25.10175 Boehringer Ingelheim Investigational Site
state: Arizona
city: Phoenix
country: United States
facility: 1245.25.10072 Boehringer Ingelheim Investigational Site
state: Arizona
city: Harrisburg
country: United States
facility: 1245.25.10048 Boehringer Ingelheim Investigational Site
state: Arkansas
city: Anaheim
country: United States
facility: 1245.25.10035 Boehringer Ingelheim Investigational Site
state: California
city: Encino
country: United States
facility: 1245.25.10103 Boehringer Ingelheim Investigational Site
state: California
city: Fresno
country: United States
facility: 1245.25.10158 Boehringer Ingelheim Investigational Site
state: California
city: Harbor City
country: United States
facility: 1245.25.10126 Boehringer Ingelheim Investigational Site
state: California
city: Huntington Park
country: United States
facility: 1245.25.10058 Boehringer Ingelheim Investigational Site
state: California
city: Lancaster
country: United States
facility: 1245.25.10001 Boehringer Ingelheim Investigational Site
state: California
city: Los Angeles
country: United States
facility: 1245.25.10102 Boehringer Ingelheim Investigational Site
state: California
city: Los Gatos
country: United States
facility: 1245.25.10047 Boehringer Ingelheim Investigational Site
state: California
city: Palm Springs
country: United States
facility: 1245.25.10118 Boehringer Ingelheim Investigational Site
state: California
city: Riverside
country: United States
facility: 1245.25.10061 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 1245.25.10040 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 1245.25.10055 Boehringer Ingelheim Investigational Site
state: California
city: San Diego
country: United States
facility: 1245.25.10193 Boehringer Ingelheim Investigational Site
state: California
city: Santa Rosa
country: United States
facility: 1245.25.10027 Boehringer Ingelheim Investigational Site
state: California
city: Stockton
country: United States
facility: 1245.25.10074 Boehringer Ingelheim Investigational Site
state: California
city: Valencia
country: United States
facility: 1245.25.10083 Boehringer Ingelheim Investigational Site
state: California
city: Colorado Springs
country: United States
facility: 1245.25.10144 Boehringer Ingelheim Investigational Site
state: Colorado
city: Denver
country: United States
facility: 1245.25.10085 Boehringer Ingelheim Investigational Site
state: Colorado
city: Denver
country: United States
facility: 1245.25.10153 Boehringer Ingelheim Investigational Site
state: Colorado
city: Norwalk
country: United States
facility: 1245.25.10066 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Waterbury
country: United States
facility: 1245.25.10038 Boehringer Ingelheim Investigational Site
state: Connecticut
city: Washington
country: United States
facility: 1245.25.10068 Boehringer Ingelheim Investigational Site
state: District of Columbia
city: Bradenton
country: United States
facility: 1245.25.10094 Boehringer Ingelheim Investigational Site
state: Florida
city: Brooksville
country: United States
facility: 1245.25.10190 Boehringer Ingelheim Investigational Site
state: Florida
city: Clearwater
country: United States
facility: 1245.25.10209 Boehringer Ingelheim Investigational Site
state: Florida
city: Cooper City
country: United States
facility: 1245.25.10212 Boehringer Ingelheim Investigational Site
state: Florida
city: Delray Beach
country: United States
facility: 1245.25.10200 Boehringer Ingelheim Investigational Site
state: Florida
city: Ft. Lauderdale
country: United States
facility: 1245.25.10033 Boehringer Ingelheim Investigational Site
state: Florida
city: Hallandale Beach
country: United States
facility: 1245.25.10202 Boehringer Ingelheim Investigational Site
state: Florida
city: Hialeah
country: United States
facility: 1245.25.10062 Boehringer Ingelheim Investigational Site
state: Florida
city: Hialeah
country: United States
facility: 1245.25.10063 Boehringer Ingelheim Investigational Site
state: Florida
city: Hialeah
country: United States
facility: 1245.25.10157 Boehringer Ingelheim Investigational Site
state: Florida
city: Jacksonville
country: United States
facility: 1245.25.10089 Boehringer Ingelheim Investigational Site
state: Florida
city: Longwood
country: United States
facility: 1245.25.10019 Boehringer Ingelheim Investigational Site
state: Florida
city: Maitland
country: United States
facility: 1245.25.10168 Boehringer Ingelheim Investigational Site
state: Florida
city: Miami
country: United States
facility: 1245.25.10018 Boehringer Ingelheim Investigational Site
state: Florida
city: Miami
country: United States
facility: 1245.25.10039 Boehringer Ingelheim Investigational Site
state: Florida
city: Miami
country: United States
facility: 1245.25.10184 Boehringer Ingelheim Investigational Site
state: Florida
city: Orlando
country: United States
facility: 1245.25.10123 Boehringer Ingelheim Investigational Site
state: Florida
city: Orlando
country: United States
facility: 1245.25.10201 Boehringer Ingelheim Investigational Site
state: Florida
city: Pembroke Pines
country: United States
facility: 1245.25.10025 Boehringer Ingelheim Investigational Site
state: Florida
city: Pembroke Pines
country: United States
facility: 1245.25.10042 Boehringer Ingelheim Investigational Site
state: Florida
city: Port Charlotte
country: United States
facility: 1245.25.10147 Boehringer Ingelheim Investigational Site
state: Florida
city: Saint Petersburg
country: United States
facility: 1245.25.10198 Boehringer Ingelheim Investigational Site
state: Florida
city: Saint Petersburg
country: United States
facility: 1245.25.10203 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 1245.25.10104 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 1245.25.10178 Boehringer Ingelheim Investigational Site
state: Florida
city: Tampa
country: United States
facility: 1245.25.10211 Boehringer Ingelheim Investigational Site
state: Florida
city: Atlanta
country: United States
facility: 1245.25.10023 Boehringer Ingelheim Investigational Site
state: Georgia
city: Columbus
country: United States
facility: 1245.25.10174 Boehringer Ingelheim Investigational Site
state: Georgia
city: Riverdale
country: United States
facility: 1245.25.10141 Boehringer Ingelheim Investigational Site
state: Georgia
city: Roswell
country: United States
facility: 1245.25.10067 Boehringer Ingelheim Investigational Site
state: Georgia
city: Honolulu
country: United States
facility: 1245.25.10022 Boehringer Ingelheim Investigational Site
state: Hawaii
city: Boise
country: United States
facility: 1245.25.10092 Boehringer Ingelheim Investigational Site
state: Idaho
city: Chicago
country: United States
facility: 1245.25.10097 Boehringer Ingelheim Investigational Site
state: Illinois
city: Evansville
country: United States
facility: 1245.25.10116 Boehringer Ingelheim Investigational Site
state: Indiana
city: Valparaiso
country: United States
facility: 1245.25.10206 Boehringer Ingelheim Investigational Site
state: Indiana
city: Wichita
country: United States
facility: 1245.25.10021 Boehringer Ingelheim Investigational Site
state: Kansas
city: Lexington
country: United States
facility: 1245.25.10186 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Louisville
country: United States
facility: 1245.25.10109 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Madisonville
country: United States
facility: 1245.25.10006 Boehringer Ingelheim Investigational Site
state: Kentucky
city: Paducah
country: United States
facility: 1245.25.10005 Boehringer Ingelheim Investigational Site
state: Kentucky
city: New Orleans
country: United States
facility: 1245.25.10020 Boehringer Ingelheim Investigational Site
state: Louisiana
city: Auburn
country: United States
facility: 1245.25.10012 Boehringer Ingelheim Investigational Site
state: Maine
city: Baltimore
country: United States
facility: 1245.25.10041 Boehringer Ingelheim Investigational Site
state: Maryland
city: Hyattsville
country: United States
facility: 1245.25.10134 Boehringer Ingelheim Investigational Site
state: Maryland
city: Towson
country: United States
facility: 1245.25.10210 Boehringer Ingelheim Investigational Site
state: Maryland
city: Springfield
country: United States
facility: 1245.25.10064 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Watertown
country: United States
facility: 1245.25.10051 Boehringer Ingelheim Investigational Site
state: Massachusetts
city: Dearborn
country: United States
facility: 1245.25.10071 Boehringer Ingelheim Investigational Site
state: Michigan
city: Flint
country: United States
facility: 1245.25.10013 Boehringer Ingelheim Investigational Site
state: Michigan
city: Petoskey
country: United States
facility: 1245.25.10107 Boehringer Ingelheim Investigational Site
state: Michigan
city: Eagan
country: United States
facility: 1245.25.10030 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Minneapolis
country: United States
facility: 1245.25.10028 Boehringer Ingelheim Investigational Site
state: Minnesota
city: Picayune
country: United States
facility: 1245.25.10176 Boehringer Ingelheim Investigational Site
state: Mississippi
city: Chesterfield
country: United States
facility: 1245.25.10011 Boehringer Ingelheim Investigational Site
state: Missouri
city: Kansas City
country: United States
facility: 1245.25.10163 Boehringer Ingelheim Investigational Site
state: Missouri
city: Great Falls
country: United States
facility: 1245.25.10148 Boehringer Ingelheim Investigational Site
state: Montana
city: Great Falls
country: United States
facility: 1245.25.10191 Boehringer Ingelheim Investigational Site
state: Montana
city: Omaha
country: United States
facility: 1245.25.10034 Boehringer Ingelheim Investigational Site
state: Nebraska
city: Flemington
country: United States
facility: 1245.25.10014 Boehringer Ingelheim Investigational Site
state: New Jersey
city: Albuquerque
country: United States
facility: 1245.25.10145 Boehringer Ingelheim Investigational Site
state: New Mexico
city: Albuquerque
country: United States
facility: 1245.25.10180 Boehringer Ingelheim Investigational Site
state: New Mexico
city: Binghamton
country: United States
facility: 1245.25.10131 Boehringer Ingelheim Investigational Site
state: New York
city: Rochester
country: United States
facility: 1245.25.10029 Boehringer Ingelheim Investigational Site
state: New York
city: Smithtown
country: United States
facility: 1245.25.10142 Boehringer Ingelheim Investigational Site
state: New York
city: Staten Island
country: United States
facility: 1245.25.10096 Boehringer Ingelheim Investigational Site
state: New York
city: Burlington
country: United States
facility: 1245.25.10196 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Calabash
country: United States
facility: 1245.25.10207 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Durham
country: United States
facility: 1245.25.10053 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Greenville
country: United States
facility: 1245.25.10010 Boehringer Ingelheim Investigational Site
state: North Carolina
city: Cincinnati
country: United States
facility: 1245.25.10060 Boehringer Ingelheim Investigational Site
state: Ohio
city: Cincinnati
country: United States
facility: 1245.25.10086 Boehringer Ingelheim Investigational Site
state: Ohio
city: Dayton
country: United States
facility: 1245.25.10137 Boehringer Ingelheim Investigational Site
state: Ohio
city: Delaware
country: United States
facility: 1245.25.10138 Boehringer Ingelheim Investigational Site
state: Ohio
city: Kettering
country: United States
facility: 1245.25.10156 Boehringer Ingelheim Investigational Site
state: Ohio
city: Marion
country: United States
facility: 1245.25.10091 Boehringer Ingelheim Investigational Site
state: Ohio
city: Zanesville
country: United States
facility: 1245.25.10192 Boehringer Ingelheim Investigational Site
state: Ohio
city: Norman
country: United States
facility: 1245.25.10114 Boehringer Ingelheim Investigational Site
state: Oklahoma
city: Eugene
country: United States
facility: 1245.25.10082 Boehringer Ingelheim Investigational Site
state: Oregon
city: Clairton
country: United States
facility: 1245.25.10154 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Clairton
country: United States
facility: 1245.25.10173 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Feasterville Trevose
country: United States
facility: 1245.25.10052 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Fleetwood
country: United States
facility: 1245.25.10069 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Greensburg
country: United States
facility: 1245.25.10172 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Indiana
country: United States
facility: 1245.25.10050 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Lansdale
country: United States
facility: 1245.25.10009 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Philadelphia
country: United States
facility: 1245.25.10214 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: 1245.25.10149 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Pittsburgh
country: United States
facility: 1245.25.10197 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Scottdale
country: United States
facility: 1245.25.10159 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Tipton
country: United States
facility: 1245.25.10162 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Uniontown
country: United States
facility: 1245.25.10146 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Yardley
country: United States
facility: 1245.25.10077 Boehringer Ingelheim Investigational Site
state: Pennsylvania
city: Anderson
country: United States
facility: 1245.25.10070 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Charleston
country: United States
facility: 1245.25.10044 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Greer
country: United States
facility: 1245.25.10002 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Hodges
country: United States
facility: 1245.25.10132 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Mt. Pleasant
country: United States
facility: 1245.25.10140 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Myrtle Beach
country: United States
facility: 1245.25.10065 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Myrtle Beach
country: United States
facility: 1245.25.10127 Boehringer Ingelheim Investigational Site
state: South Carolina
city: North Myrtle Beach
country: United States
facility: 1245.25.10170 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Spartanburg
country: United States
facility: 1245.25.10129 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Union
country: United States
facility: 1245.25.10171 Boehringer Ingelheim Investigational Site
state: South Carolina
city: Bristol
country: United States
facility: 1245.25.10054 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Chattanooga
country: United States
facility: 1245.25.10036 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Chattanooga
country: United States
facility: 1245.25.10057 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Kingsport
country: United States
facility: 1245.25.10046 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Memphis
country: United States
facility: 1245.25.10143 Boehringer Ingelheim Investigational Site
state: Tennessee
city: Corpus Christi
country: United States
facility: 1245.25.10075 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 1245.25.10007 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 1245.25.10026 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 1245.25.10100 Boehringer Ingelheim Investigational Site
state: Texas
city: Dallas
country: United States
facility: 1245.25.10165 Boehringer Ingelheim Investigational Site
state: Texas
city: Fort Worth
country: United States
facility: 1245.25.10169 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 1245.25.10003 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 1245.25.10125 Boehringer Ingelheim Investigational Site
state: Texas
city: Houston
country: United States
facility: 1245.25.10189 Boehringer Ingelheim Investigational Site
state: Texas
city: Lubbock
country: United States
facility: 1245.25.10119 Boehringer Ingelheim Investigational Site
state: Texas
city: New Braunfels
country: United States
facility: 1245.25.10078 Boehringer Ingelheim Investigational Site
state: Texas
city: Odessa
country: United States
facility: 1245.25.10076 Boehringer Ingelheim Investigational Site
state: Texas
city: Pearland
country: United States
facility: 1245.25.10133 Boehringer Ingelheim Investigational Site
state: Texas
city: Plano
country: United States
facility: 1245.25.10160 Boehringer Ingelheim Investigational Site
state: Texas
city: Richardson
country: United States
facility: 1245.25.10177 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 1245.25.10049 Boehringer Ingelheim Investigational Site
state: Texas
city: San Antonio
country: United States
facility: 1245.25.10161 Boehringer Ingelheim Investigational Site
state: Texas
city: Bountiful
country: United States
facility: 1245.25.10185 Boehringer Ingelheim Investigational Site
state: Utah
city: Draper
country: United States
facility: 1245.25.10155 Boehringer Ingelheim Investigational Site
state: Utah
city: Midvale
country: United States
facility: 1245.25.10079 Boehringer Ingelheim Investigational Site
state: Utah
city: Salt Lake City
country: United States
facility: 1245.25.10080 Boehringer Ingelheim Investigational Site
state: Utah
city: South Ogden
country: United States
facility: 1245.25.10087 Boehringer Ingelheim Investigational Site
state: Utah
city: Burke
country: United States
facility: 1245.25.10218 Boehringer Ingelheim Investigational Site
state: Virginia
city: Norfolk
country: United States
facility: 1245.25.10004 Boehringer Ingelheim Investigational Site
state: Virginia
city: South Chesterfield
country: United States
facility: 1245.25.10111 Boehringer Ingelheim Investigational Site
state: Virginia
city: Spokane
country: United States
facility: 1245.25.10115 Boehringer Ingelheim Investigational Site
state: Washington
city: Spokane
country: United States
facility: 1245.25.10216 Boehringer Ingelheim Investigational Site
state: Washington
city: Tacoma
country: United States
facility: 1245.25.10017 Boehringer Ingelheim Investigational Site
state: Washington
city: Walla Walla
country: United States
facility: 1245.25.10016 Boehringer Ingelheim Investigational Site
state: Washington
city: Charleston
country: United States
facility: 1245.25.10187 Boehringer Ingelheim Investigational Site
state: West Virginia
city: Morgantown
country: United States
facility: 1245.25.10182 Boehringer Ingelheim Investigational Site
state: West Virginia
city: Madison
country: United States
facility: 1245.25.10098 Boehringer Ingelheim Investigational Site
state: Wisconsin
city: Buenos Aires
country: Argentina
facility: 1245.25.54012 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 1245.25.54001 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 1245.25.54006 Boehringer Ingelheim Investigational Site
city: Capital Federal
country: Argentina
facility: 1245.25.54013 Boehringer Ingelheim Investigational Site
city: Cordoba
country: Argentina
facility: 1245.25.54010 Boehringer Ingelheim Investigational Site
city: Cordoba
country: Argentina
facility: 1245.25.54011 Boehringer Ingelheim Investigational Site
city: Córdoba
country: Argentina
facility: 1245.25.54002 Boehringer Ingelheim Investigational Site
city: Córdoba
country: Argentina
facility: 1245.25.54003 Boehringer Ingelheim Investigational Site
city: Parque Velez Sarfield
country: Argentina
facility: 1245.25.54005 Boehringer Ingelheim Investigational Site
city: Rosario
country: Argentina
facility: 1245.25.54008 Boehringer Ingelheim Investigational Site
city: Rosario
country: Argentina
facility: 1245.25.54009 Boehringer Ingelheim Investigational Site
city: Herston
country: Australia
facility: 1245.25.61003 Boehringer Ingelheim Investigational Site
state: Queensland
city: Ashford
country: Australia
facility: 1245.25.61001 Boehringer Ingelheim Investigational Site
state: South Australia
city: Fullarton
country: Australia
facility: 1245.25.61002 Boehringer Ingelheim Investigational Site
state: South Australia
city: Feldkirch
country: Austria
facility: 1245.25.43008 Boehringer Ingelheim Investigational Site
city: Graz
country: Austria
facility: 1245.25.43006 Boehringer Ingelheim Investigational Site
city: Innsbruck
country: Austria
facility: 1245.25.43016 Boehringer Ingelheim Investigational Site
city: Salzburg
country: Austria
facility: 1245.25.43005 Boehringer Ingelheim Investigational Site
city: St. Stefan
country: Austria
facility: 1245.25.43015 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1245.25.43001 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1245.25.43007 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1245.25.43009 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1245.25.43010 Boehringer Ingelheim Investigational Site
city: Wien
country: Austria
facility: 1245.25.43013 Boehringer Ingelheim Investigational Site
city: Bonheiden
country: Belgium
facility: 1245.25.32010 Boehringer Ingelheim Investigational Site
city: Brussel
country: Belgium
facility: 1245.25.32030 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 1245.25.32008 Boehringer Ingelheim Investigational Site
city: Bruxelles
country: Belgium
facility: 1245.25.32011 Boehringer Ingelheim Investigational Site
city: De Pinte
country: Belgium
facility: 1245.25.32003 Boehringer Ingelheim Investigational Site
city: Edegem
country: Belgium
facility: 1245.25.32002 Boehringer Ingelheim Investigational Site
city: Genk
country: Belgium
facility: 1245.25.32004 Boehringer Ingelheim Investigational Site
city: Halen
country: Belgium
facility: 1245.25.32029 Boehringer Ingelheim Investigational Site
city: Hasselt
country: Belgium
facility: 1245.25.32009 Boehringer Ingelheim Investigational Site
city: Huy
country: Belgium
facility: 1245.25.32007 Boehringer Ingelheim Investigational Site
city: La Louvière
country: Belgium
facility: 1245.25.32013 Boehringer Ingelheim Investigational Site
city: Leuven
country: Belgium
facility: 1245.25.32012 Boehringer Ingelheim Investigational Site
city: Liège
country: Belgium
facility: 1245.25.32001 Boehringer Ingelheim Investigational Site
city: Liège
country: Belgium
facility: 1245.25.32028 Boehringer Ingelheim Investigational Site
city: Massemen-Wetteren
country: Belgium
facility: 1245.25.32005 Boehringer Ingelheim Investigational Site
city: Oostham
country: Belgium
facility: 1245.25.32014 Boehringer Ingelheim Investigational Site
city: Belo Horizonte
country: Brazil
facility: 1245.25.55019 Boehringer Ingelheim Investigational Site
city: Belém
country: Brazil
facility: 1245.25.55014 Boehringer Ingelheim Investigational Site
city: Boqueirão
country: Brazil
facility: 1245.25.55007 Boehringer Ingelheim Investigational Site
city: Brasília
country: Brazil
facility: 1245.25.55015 Boehringer Ingelheim Investigational Site
city: Campinas
country: Brazil
facility: 1245.25.55027 Boehringer Ingelheim Investigational Site
city: Campinas
country: Brazil
facility: 1245.25.55028 Boehringer Ingelheim Investigational Site
city: Curitiba
country: Brazil
facility: 1245.25.55025 Boehringer Ingelheim Investigational Site
city: Fortaleza
country: Brazil
facility: 1245.25.55026 Boehringer Ingelheim Investigational Site
city: Goiânia
country: Brazil
facility: 1245.25.55009 Boehringer Ingelheim Investigational Site
city: Higienópolis
country: Brazil
facility: 1245.25.55002 Boehringer Ingelheim Investigational Site
city: Marilia
country: Brazil
facility: 1245.25.55017 Boehringer Ingelheim Investigational Site
city: Maringá
country: Brazil
facility: 1245.25.55022 Boehringer Ingelheim Investigational Site
city: Porto Alegre
country: Brazil
facility: 1245.25.55008 Boehringer Ingelheim Investigational Site
city: Porto Alegre
country: Brazil
facility: 1245.25.55016 Boehringer Ingelheim Investigational Site
city: Porto Alegre
country: Brazil
facility: 1245.25.55020 Boehringer Ingelheim Investigational Site
city: Ribeirão Preto
country: Brazil
facility: 1245.25.55012 Boehringer Ingelheim Investigational Site
city: São José do Rio Preto
country: Brazil
facility: 1245.25.55013 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 1245.25.55004 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 1245.25.55010 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 1245.25.55018 Boehringer Ingelheim Investigational Site
city: São Paulo
country: Brazil
facility: 1245.25.55023 Boehringer Ingelheim Investigational Site
city: Vila Albuquerque
country: Brazil
facility: 1245.25.55006 Boehringer Ingelheim Investigational Site
city: Vila Clementino
country: Brazil
facility: 1245.25.55003 Boehringer Ingelheim Investigational Site
city: Vila Leopoldina
country: Brazil
facility: 1245.25.55005 Boehringer Ingelheim Investigational Site
city: Villa Clementino
country: Brazil
facility: 1245.25.55001 Boehringer Ingelheim Investigational Site
city: Vancouver
country: Canada
facility: 1245.25.20047 Boehringer Ingelheim Investigational Site
state: British Columbia
city: Winnipeg
country: Canada
facility: 1245.25.20048 Boehringer Ingelheim Investigational Site
state: Manitoba
city: Halifax
country: Canada
facility: 1245.25.20026 Boehringer Ingelheim Investigational Site
state: Nova Scotia
city: Brampton
country: Canada
facility: 1245.25.20045 Boehringer Ingelheim Investigational Site
state: Ontario
city: Burlington
country: Canada
facility: 1245.25.20042 Boehringer Ingelheim Investigational Site
state: Ontario
city: Newmarket
country: Canada
facility: 1245.25.20009 Boehringer Ingelheim Investigational Site
state: Ontario
city: Niagara Falls
country: Canada
facility: 1245.25.20044 Boehringer Ingelheim Investigational Site
state: Ontario
city: Ottawa
country: Canada
facility: 1245.25.20013 Boehringer Ingelheim Investigational Site
state: Ontario
city: Toronto
country: Canada
facility: 1245.25.20049 Boehringer Ingelheim Investigational Site
state: Ontario
city: Gatineau
country: Canada
facility: 1245.25.20050 Boehringer Ingelheim Investigational Site
state: Quebec
city: Longueuil
country: Canada
facility: 1245.25.20043 Boehringer Ingelheim Investigational Site
state: Quebec
city: Longueuil
country: Canada
facility: 1245.25.20046 Boehringer Ingelheim Investigational Site
state: Quebec
city: Saskatoon
country: Canada
facility: 1245.25.20041 Boehringer Ingelheim Investigational Site
state: Saskatchewan
city: Armenia
country: Colombia
facility: 1245.25.57010 Boehringer Ingelheim Investigational Site
city: Barranquilla
country: Colombia
facility: 1245.25.57004 Boehringer Ingelheim Investigational Site
city: Bogotá
country: Colombia
facility: 1245.25.57001 Boehringer Ingelheim Investigational Site
city: Bogotá
country: Colombia
facility: 1245.25.57003 Boehringer Ingelheim Investigational Site
city: Bogotá
country: Colombia
facility: 1245.25.57011 Boehringer Ingelheim Investigational Site
city: Floridablanca
country: Colombia
facility: 1245.25.57006 Boehringer Ingelheim Investigational Site
city: Medellín
country: Colombia
facility: 1245.25.57009 Boehringer Ingelheim Investigational Site
city: Karlovac
country: Croatia
facility: 1245.25.71005 Boehringer Ingelheim Investigational Site
city: Krapinske Toplice
country: Croatia
facility: 1245.25.71001 Boehringer Ingelheim Investigational Site
city: Osijek
country: Croatia
facility: 1245.25.71006 Boehringer Ingelheim Investigational Site
city: Rijeka
country: Croatia
facility: 1245.25.71003 Boehringer Ingelheim Investigational Site
city: Zagreb
country: Croatia
facility: 1245.25.71002 Boehringer Ingelheim Investigational Site
city: Zagreb
country: Croatia
facility: 1245.25.71004 Boehringer Ingelheim Investigational Site
city: Brno
country: Czech Republic
facility: 1245.25.42020 Boehringer Ingelheim Investigational Site
city: Jindrichuv Hradec
country: Czech Republic
facility: 1245.25.42018 Boehringer Ingelheim Investigational Site
city: Praha 3
country: Czech Republic
facility: 1245.25.42015 Boehringer Ingelheim Investigational Site
city: Usti nad Labem
country: Czech Republic
facility: 1245.25.42019 Boehringer Ingelheim Investigational Site
city: Frederiksberg
country: Denmark
facility: 1245.25.45006 Boehringer Ingelheim Investigational Site
city: Gentofte
country: Denmark
facility: 1245.25.45003 Boehringer Ingelheim Investigational Site
city: Helsingør
country: Denmark
facility: 1245.25.45007 Boehringer Ingelheim Investigational Site
city: København NV
country: Denmark
facility: 1245.25.45002 Boehringer Ingelheim Investigational Site
city: Randers NØ
country: Denmark
facility: 1245.25.45004 Boehringer Ingelheim Investigational Site
city: Slagelse
country: Denmark
facility: 1245.25.45005 Boehringer Ingelheim Investigational Site
city: Tallinn
country: Estonia
facility: 1245.25.37003 Boehringer Ingelheim Investigational Site
city: Tallin
country: Estonia
facility: 1245.25.37002 Boehringer Ingelheim Investigational Site
city: Tallin
country: Estonia
facility: 1245.25.37005 Boehringer Ingelheim Investigational Site
city: Tartu
country: Estonia
facility: 1245.25.37001 Boehringer Ingelheim Investigational Site
city: Tartu
country: Estonia
facility: 1245.25.37004 Boehringer Ingelheim Investigational Site
city: Amiens
country: France
facility: 1245.25.33022 Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1245.25.33033 Boehringer Ingelheim Investigational Site
city: Angers
country: France
facility: 1245.25.33034 Boehringer Ingelheim Investigational Site
city: Bourg des cptes
country: France
facility: 1245.25.33030 Boehringer Ingelheim Investigational Site
city: Corbeil Essonnes
country: France
facility: 1245.25.33023 Boehringer Ingelheim Investigational Site
city: Derval
country: France
facility: 1245.25.33024 Boehringer Ingelheim Investigational Site
city: Equeurdreville Haineville
country: France
facility: 1245.25.33029 Boehringer Ingelheim Investigational Site
city: Fleury sur Orne
country: France
facility: 1245.25.33027 Boehringer Ingelheim Investigational Site
city: Grenoble
country: France
facility: 1245.25.33021 Boehringer Ingelheim Investigational Site
city: La Rochelle Cedex 1
country: France
facility: 1245.25.33003 Boehringer Ingelheim Investigational Site
city: Le Creusot
country: France
facility: 1245.25.33032 Boehringer Ingelheim Investigational Site
city: Narbonne Cedex
country: France
facility: 1245.25.33004 Boehringer Ingelheim Investigational Site
city: Pessac
country: France
facility: 1245.25.33047 Boehringer Ingelheim Investigational Site
city: Poitiers
country: France
facility: 1245.25.33046 Boehringer Ingelheim Investigational Site
city: Saint Priez en Jarez
country: France
facility: 1245.25.33025 Boehringer Ingelheim Investigational Site
city: Tours
country: France
facility: 1245.25.33035 Boehringer Ingelheim Investigational Site
city: Batumi
country: Georgia
facility: 1245.25.99001 Boehringer Ingelheim Investigational Site
city: Kutaisi
country: Georgia
facility: 1245.25.99003 Boehringer Ingelheim Investigational Site
city: Tbilisi
country: Georgia
facility: 1245.25.99002 Boehringer Ingelheim Investigational Site
city: Tbilisi
country: Georgia
facility: 1245.25.99004 Boehringer Ingelheim Investigational Site
city: Tbilisi
country: Georgia
facility: 1245.25.99005 Boehringer Ingelheim Investigational Site
city: Tbilisi
country: Georgia
facility: 1245.25.99006 Boehringer Ingelheim Investigational Site
city: Tbilisi
country: Georgia
facility: 1245.25.99007 Boehringer Ingelheim Investigational Site
city: Tbilisi
country: Georgia
facility: 1245.25.99008 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 1245.25.30002 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 1245.25.30003 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 1245.25.30004 Boehringer Ingelheim Investigational Site
city: Athens
country: Greece
facility: 1245.25.30007 Boehringer Ingelheim Investigational Site
city: Larissa
country: Greece
facility: 1245.25.30005 Boehringer Ingelheim Investigational Site
city: Nikaia
country: Greece
facility: 1245.25.30001 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 1245.25.30006 Boehringer Ingelheim Investigational Site
city: Thessaloniki
country: Greece
facility: 1245.25.30008 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 1245.25.85201 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 1245.25.85205 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 1245.25.85207 Boehringer Ingelheim Investigational Site
city: Hong Kong
country: Hong Kong
facility: 1245.25.85208 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1245.25.36002 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1245.25.36004 Boehringer Ingelheim Investigational Site
city: Budapest
country: Hungary
facility: 1245.25.36008 Boehringer Ingelheim Investigational Site
city: Dunaujvaros
country: Hungary
facility: 1245.25.36006 Boehringer Ingelheim Investigational Site
city: Gyula
country: Hungary
facility: 1245.25.36001 Boehringer Ingelheim Investigational Site
city: Kisvarda
country: Hungary
facility: 1245.25.36010 Boehringer Ingelheim Investigational Site
city: Szekszard
country: Hungary
facility: 1245.25.36003 Boehringer Ingelheim Investigational Site
city: Szikszo
country: Hungary
facility: 1245.25.36011 Boehringer Ingelheim Investigational Site
city: Ahmedabad
country: India
facility: 1245.25.91307 Boehringer Ingelheim Investigational Site
city: Bangalore
country: India
facility: 1245.25.91302 Boehringer Ingelheim Investigational Site
city: Bangalore
country: India
facility: 1245.25.91317 Boehringer Ingelheim Investigational Site
city: Bangalore
country: India
facility: 1245.25.91319 Boehringer Ingelheim Investigational Site
city: Bangalore
country: India
facility: 1245.25.91320 Boehringer Ingelheim Investigational Site
city: Chennai
country: India
facility: 1245.25.91303 Boehringer Ingelheim Investigational Site
city: Cochin
country: India
facility: 1245.25.91315 Boehringer Ingelheim Investigational Site
city: Hyderabad
country: India
facility: 1245.25.91311 Boehringer Ingelheim Investigational Site
city: Indore
country: India
facility: 1245.25.91318 Boehringer Ingelheim Investigational Site
city: Jaipur
country: India
facility: 1245.25.91305 Boehringer Ingelheim Investigational Site
city: Jalandhar
country: India
facility: 1245.25.91309 Boehringer Ingelheim Investigational Site
city: Nagpur
country: India
facility: 1245.25.91313 Boehringer Ingelheim Investigational Site
city: Nagpur
country: India
facility: 1245.25.91324 Boehringer Ingelheim Investigational Site
city: Nashik, Maharashtra
country: India
facility: 1245.25.91301 Boehringer Ingelheim Investigational Site
city: Pune
country: India
facility: 1245.25.91308 Boehringer Ingelheim Investigational Site
city: Secunderabad
country: India
facility: 1245.25.91316 Boehringer Ingelheim Investigational Site
city: Varanasi
country: India
facility: 1245.25.91321 Boehringer Ingelheim Investigational Site
city: Vijaywada
country: India
facility: 1245.25.91314 Boehringer Ingelheim Investigational Site
city: Denpasar, Bali
country: Indonesia
facility: 1245.25.62006 Boehringer Ingelheim Investigational Site
city: Depok
country: Indonesia
facility: 1245.25.62009 Boehringer Ingelheim Investigational Site
city: Jakarta
country: Indonesia
facility: 1245.25.62002 Boehringer Ingelheim Investigational Site
city: Jakarta
country: Indonesia
facility: 1245.25.62008 Boehringer Ingelheim Investigational Site
city: Jakarta
country: Indonesia
facility: 1245.25.62010 Boehringer Ingelheim Investigational Site
city: Malang
country: Indonesia
facility: 1245.25.62004 Boehringer Ingelheim Investigational Site
city: Surabaya
country: Indonesia
facility: 1245.25.62003 Boehringer Ingelheim Investigational Site
city: Yogyakarta
country: Indonesia
facility: 1245.25.62001 Boehringer Ingelheim Investigational Site
city: Afula
country: Israel
facility: 1245.25.97003 Boehringer Ingelheim Investigational Site
city: Hadera
country: Israel
facility: 1245.25.97006 Boehringer Ingelheim Investigational Site
city: Haifa
country: Israel
facility: 1245.25.97008 Boehringer Ingelheim Investigational Site
city: Holon
country: Israel
facility: 1245.25.97009 Boehringer Ingelheim Investigational Site
city: Nahariya
country: Israel
facility: 1245.25.97005 Boehringer Ingelheim Investigational Site
city: Safed
country: Israel
facility: 1245.25.97001 Boehringer Ingelheim Investigational Site
city: Zerifin
country: Israel
facility: 1245.25.97002 Boehringer Ingelheim Investigational Site
city: Bologna
country: Italy
facility: 1245.25.39007 Boehringer Ingelheim Investigational Site
city: Campobasso
country: Italy
facility: 1245.25.39002 Boehringer Ingelheim Investigational Site
city: Catanzaro
country: Italy
facility: 1245.25.39008 Boehringer Ingelheim Investigational Site
city: Chieti
country: Italy
facility: 1245.25.39010 Boehringer Ingelheim Investigational Site
city: Ferrara
country: Italy
facility: 1245.25.39024 Boehringer Ingelheim Investigational Site
city: Firenze
country: Italy
facility: 1245.25.39009 Boehringer Ingelheim Investigational Site
city: Foggia
country: Italy
facility: 1245.25.39005 Boehringer Ingelheim Investigational Site
city: Napoli
country: Italy
facility: 1245.25.39004 Boehringer Ingelheim Investigational Site
city: Padova
country: Italy
facility: 1245.25.39006 Boehringer Ingelheim Investigational Site
city: Pisa
country: Italy
facility: 1245.25.39001 Boehringer Ingelheim Investigational Site
city: Roma
country: Italy
facility: 1245.25.39003 Boehringer Ingelheim Investigational Site
city: Roma
country: Italy
facility: 1245.25.39011 Boehringer Ingelheim Investigational Site
city: Roma
country: Italy
facility: 1245.25.39012 Boehringer Ingelheim Investigational Site
city: Roma
country: Italy
facility: 1245.25.39014 Boehringer Ingelheim Investigational Site
city: Venezia
country: Italy
facility: 1245.25.39013 Boehringer Ingelheim Investigational Site
city: Chuo-ku, tokyo
country: Japan
facility: 1245.25.81008 Boehringer Ingelheim Investigational Site
city: Gifushi, Gifu
country: Japan
facility: 1245.25.81010 Boehringer Ingelheim Investigational Site
city: Hanyushi, Saitama
country: Japan
facility: 1245.25.81002 Boehringer Ingelheim Investigational Site
city: Kamigyo-ku, Kyotoshi, Kyoto
country: Japan
facility: 1245.25.81013 Boehringer Ingelheim Investigational Site
city: Kishiwadashi. Osaka
country: Japan
facility: 1245.25.81003 Boehringer Ingelheim Investigational Site
city: Kita-ku, Nagoyashi, Aichi
country: Japan
facility: 1245.25.81012 Boehringer Ingelheim Investigational Site
city: Kumamoto-shi, Kumamoto
country: Japan
facility: 1245.25.81014 Boehringer Ingelheim Investigational Site
city: Matsudoshi, Chiba
country: Japan
facility: 1245.25.81001 Boehringer Ingelheim Investigational Site
city: Mitoshi, Ibaraki
country: Japan
facility: 1245.25.81006 Boehringer Ingelheim Investigational Site
city: Nishi-ku, Sapporoshi, Hokkaido
country: Japan
facility: 1245.25.81005 Boehringer Ingelheim Investigational Site
city: Nodashi, Chiba
country: Japan
facility: 1245.25.81007 Boehringer Ingelheim Investigational Site
city: Shimajiri-gun,Okinawa
country: Japan
facility: 1245.25.81004 Boehringer Ingelheim Investigational Site
city: Toyamashi, Toyama
country: Japan
facility: 1245.25.81009 Boehringer Ingelheim Investigational Site
city: Toyoakeshi, Aichi
country: Japan
facility: 1245.25.81015 Boehringer Ingelheim Investigational Site
city: Busan
country: Korea, Republic of
facility: 1245.25.82030 Boehringer Ingelheim Investigational Site
city: Daegu
country: Korea, Republic of
facility: 1245.25.82018 Boehringer Ingelheim Investigational Site
city: Daejeon
country: Korea, Republic of
facility: 1245.25.82021 Boehringer Ingelheim Investigational Site
city: Daejoen
country: Korea, Republic of
facility: 1245.25.82031 Boehringer Ingelheim Investigational Site
city: Goyang
country: Korea, Republic of
facility: 1245.25.82027 Boehringer Ingelheim Investigational Site
city: Gwangju
country: Korea, Republic of
facility: 1245.25.82022 Boehringer Ingelheim Investigational Site
city: Incheon
country: Korea, Republic of
facility: 1245.25.82029 Boehringer Ingelheim Investigational Site
city: Pusan
country: Korea, Republic of
facility: 1245.25.82017 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1245.25.82015 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1245.25.82016 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1245.25.82019 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1245.25.82020 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1245.25.82023 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1245.25.82024 Boehringer Ingelheim Investigational Site
city: Seoul
country: Korea, Republic of
facility: 1245.25.82025 Boehringer Ingelheim Investigational Site
city: Suwon
country: Korea, Republic of
facility: 1245.25.82026 Boehringer Ingelheim Investigational Site
city: Wonju
country: Korea, Republic of
facility: 1245.25.82028 Boehringer Ingelheim Investigational Site
city: Johor Bahru
country: Malaysia
facility: 1245.25.60019 Boehringer Ingelheim Investigational Site
city: Kedah
country: Malaysia
facility: 1245.25.60020 Boehringer Ingelheim Investigational Site
city: Kelantan
country: Malaysia
facility: 1245.25.60013 Boehringer Ingelheim Investigational Site
city: Kota Kinabalu
country: Malaysia
facility: 1245.25.60015 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 1245.25.60012 Boehringer Ingelheim Investigational Site
city: Kuala Lumpur
country: Malaysia
facility: 1245.25.60017 Boehringer Ingelheim Investigational Site
city: Pahang
country: Malaysia
facility: 1245.25.60004 Boehringer Ingelheim Investigational Site
city: Selangor Darul Ehsan
country: Malaysia
facility: 1245.25.60018 Boehringer Ingelheim Investigational Site
city: Selangor
country: Malaysia
facility: 1245.25.60016 Boehringer Ingelheim Investigational Site
city: Selangor
country: Malaysia
facility: 1245.25.60021 Boehringer Ingelheim Investigational Site
city: Colonia Americana
country: Mexico
facility: 1245.25.52009 Boehringer Ingelheim Investigational Site
city: Distrito Federal
country: Mexico
facility: 1245.25.52007 Boehringer Ingelheim Investigational Site
city: Ladron de Guevara
country: Mexico
facility: 1245.25.52013 Boehringer Ingelheim Investigational Site
city: Los Robles
country: Mexico
facility: 1245.25.52010 Boehringer Ingelheim Investigational Site
city: Monterrey
country: Mexico
facility: 1245.25.52001 Boehringer Ingelheim Investigational Site
city: Reforma Social
country: Mexico
facility: 1245.25.52011 Boehringer Ingelheim Investigational Site
city: San Lucas tepetlcalco
country: Mexico
facility: 1245.25.52012 Boehringer Ingelheim Investigational Site
city: Amersfoort
country: Netherlands
facility: 1245.25.31015 Boehringer Ingelheim Investigational Site
city: Apeldoorn
country: Netherlands
facility: 1245.25.31013 Boehringer Ingelheim Investigational Site
city: Baarle - Nassau
country: Netherlands
facility: 1245.25.31036 Boehringer Ingelheim Investigational Site
city: Delft
country: Netherlands
facility: 1245.25.31032 Boehringer Ingelheim Investigational Site
city: Den Helder
country: Netherlands
facility: 1245.25.31026 Boehringer Ingelheim Investigational Site
city: Geleen
country: Netherlands
facility: 1245.25.31012 Boehringer Ingelheim Investigational Site
city: Hardenberg
country: Netherlands
facility: 1245.25.31017 Boehringer Ingelheim Investigational Site
city: Heerlen
country: Netherlands
facility: 1245.25.31035 Boehringer Ingelheim Investigational Site
city: Hoogeveen
country: Netherlands
facility: 1245.25.31011 Boehringer Ingelheim Investigational Site
city: Hoogezand
country: Netherlands
facility: 1245.25.31029 Boehringer Ingelheim Investigational Site
city: Hoogwoud
country: Netherlands
facility: 1245.25.31023 Boehringer Ingelheim Investigational Site
city: Maastricht
country: Netherlands
facility: 1245.25.31009 Boehringer Ingelheim Investigational Site
city: Meppel
country: Netherlands
facility: 1245.25.31031 Boehringer Ingelheim Investigational Site
city: Nijverdal
country: Netherlands
facility: 1245.25.31024 Boehringer Ingelheim Investigational Site
city: Rotterdam
country: Netherlands
facility: 1245.25.31014 Boehringer Ingelheim Investigational Site
city: Rotterdam
country: Netherlands
facility: 1245.25.31033 Boehringer Ingelheim Investigational Site
city: Schiedam
country: Netherlands
facility: 1245.25.31030 Boehringer Ingelheim Investigational Site
city: Utrecht
country: Netherlands
facility: 1245.25.31002 Boehringer Ingelheim Investigational Site
city: Wildervank
country: Netherlands
facility: 1245.25.31028 Boehringer Ingelheim Investigational Site
city: Zutphen
country: Netherlands
facility: 1245.25.31034 Boehringer Ingelheim Investigational Site
city: Christchurch
country: New Zealand
facility: 1245.25.64004 Boehringer Ingelheim Investigational Site
city: Grafton / Auckland
country: New Zealand
facility: 1245.25.64001 Boehringer Ingelheim Investigational Site
city: Wellington
country: New Zealand
facility: 1245.25.64003 Boehringer Ingelheim Investigational Site
city: Fornebu
country: Norway
facility: 1245.25.47002 Boehringer Ingelheim Investigational Site
city: Gjøvik
country: Norway
facility: 1245.25.47004 Boehringer Ingelheim Investigational Site
city: Kløfta
country: Norway
facility: 1245.25.47009 Boehringer Ingelheim Investigational Site
city: Kongsvinger
country: Norway
facility: 1245.25.47008 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 1245.25.47001 Boehringer Ingelheim Investigational Site
city: Oslo
country: Norway
facility: 1245.25.47006 Boehringer Ingelheim Investigational Site
city: Trondheim
country: Norway
facility: 1245.25.47007 Boehringer Ingelheim Investigational Site
city: Tynset
country: Norway
facility: 1245.25.47005 Boehringer Ingelheim Investigational Site
city: Arequipa
country: Peru
facility: 1245.25.51001 Boehringer Ingelheim Investigational Site
city: Arequipa
country: Peru
facility: 1245.25.51008 Boehringer Ingelheim Investigational Site
city: Bellavista
country: Peru
facility: 1245.25.51002 Boehringer Ingelheim Investigational Site
city: El Agustino
country: Peru
facility: 1245.25.51004 Boehringer Ingelheim Investigational Site
city: Ica
country: Peru
facility: 1245.25.51006 Boehringer Ingelheim Investigational Site
city: Jesus Maria
country: Peru
facility: 1245.25.51003 Boehringer Ingelheim Investigational Site
city: Lima
country: Peru
facility: 1245.25.51007 Boehringer Ingelheim Investigational Site
city: Lima
country: Peru
facility: 1245.25.51009 Boehringer Ingelheim Investigational Site
city: Lima
country: Peru
facility: 1245.25.51010 Boehringer Ingelheim Investigational Site
city: Lima
country: Peru
facility: 1245.25.51011 Boehringer Ingelheim Investigational Site
city: Miraflores
country: Peru
facility: 1245.25.51005 Boehringer Ingelheim Investigational Site
city: Cavite City
country: Philippines
facility: 1245.25.63016 Boehringer Ingelheim Investigational Site
city: Cebu
country: Philippines
facility: 1245.25.63002 Boehringer Ingelheim Investigational Site
city: Davao
country: Philippines
facility: 1245.25.63003 Boehringer Ingelheim Investigational Site
city: Jaro Iloilo City
country: Philippines
facility: 1245.25.63020 Boehringer Ingelheim Investigational Site
city: Manila
country: Philippines
facility: 1245.25.63001 Boehringer Ingelheim Investigational Site
city: Manila
country: Philippines
facility: 1245.25.63004 Boehringer Ingelheim Investigational Site
city: Manila
country: Philippines
facility: 1245.25.63018 Boehringer Ingelheim Investigational Site
city: Marikina City
country: Philippines
facility: 1245.25.63009 Boehringer Ingelheim Investigational Site
city: Marikina City
country: Philippines
facility: 1245.25.63021 Boehringer Ingelheim Investigational Site
city: Tarlac
country: Philippines
facility: 1245.25.63019 Boehringer Ingelheim Investigational Site
city: Gdansk
country: Poland
facility: 1245.25.48013 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 1245.25.48004 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 1245.25.48009 Boehringer Ingelheim Investigational Site
city: Lodz
country: Poland
facility: 1245.25.48010 Boehringer Ingelheim Investigational Site
city: Lublin
country: Poland
facility: 1245.25.48001 Boehringer Ingelheim Investigational Site
city: Oswiecim
country: Poland
facility: 1245.25.48014 Boehringer Ingelheim Investigational Site
city: Poznan
country: Poland
facility: 1245.25.48002 Boehringer Ingelheim Investigational Site
city: Pulawy
country: Poland
facility: 1245.25.48008 Boehringer Ingelheim Investigational Site
city: Ruda Slaska
country: Poland
facility: 1245.25.48007 Boehringer Ingelheim Investigational Site
city: Torun
country: Poland
facility: 1245.25.48005 Boehringer Ingelheim Investigational Site
city: Torun
country: Poland
facility: 1245.25.48011 Boehringer Ingelheim Investigational Site
city: Amadora
country: Portugal
facility: 1245.25.35006 Boehringer Ingelheim Investigational Site
city: Coimbra
country: Portugal
facility: 1245.25.35004 Boehringer Ingelheim Investigational Site
city: Faro
country: Portugal
facility: 1245.25.35018 Boehringer Ingelheim Investigational Site
city: Funchal
country: Portugal
facility: 1245.25.35021 Boehringer Ingelheim Investigational Site
city: Leiria
country: Portugal
facility: 1245.25.35008 Boehringer Ingelheim Investigational Site
city: Lisboa
country: Portugal
facility: 1245.25.35001 Boehringer Ingelheim Investigational Site
city: Lisboa
country: Portugal
facility: 1245.25.35002 Boehringer Ingelheim Investigational Site
city: Lisboa
country: Portugal
facility: 1245.25.35015 Boehringer Ingelheim Investigational Site
city: Lisboa
country: Portugal
facility: 1245.25.35017 Boehringer Ingelheim Investigational Site
city: Porto
country: Portugal
facility: 1245.25.35011 Boehringer Ingelheim Investigational Site
city: Santiago do Cacém
country: Portugal
facility: 1245.25.35005 Boehringer Ingelheim Investigational Site
city: Torres Novas
country: Portugal
facility: 1245.25.35020 Boehringer Ingelheim Investigational Site
city: Viana do Castelo
country: Portugal
facility: 1245.25.35014 Boehringer Ingelheim Investigational Site
city: Vila Nova de Gaia
country: Portugal
facility: 1245.25.35019 Boehringer Ingelheim Investigational Site
city: Alba Iulia
country: Romania
facility: 1245.25.40008 Boehringer Ingelheim Investigational Site
city: Baia Mare Maramures
country: Romania
facility: 1245.25.40011 Boehringer Ingelheim Investigational Site
city: Bucharest
country: Romania
facility: 1245.25.40003 Boehringer Ingelheim Investigational Site
city: Bucharest
country: Romania
facility: 1245.25.40007 Boehringer Ingelheim Investigational Site
city: Constanta
country: Romania
facility: 1245.25.40005 Boehringer Ingelheim Investigational Site
city: Craiova
country: Romania
facility: 1245.25.40002 Boehringer Ingelheim Investigational Site
city: Craiova
country: Romania
facility: 1245.25.40006 Boehringer Ingelheim Investigational Site
city: Oradea
country: Romania
facility: 1245.25.40009 Boehringer Ingelheim Investigational Site
city: Targu-Mures
country: Romania
facility: 1245.25.40010 Boehringer Ingelheim Investigational Site
city: Barnaul
country: Russian Federation
facility: 1245.25.70019 Boehringer Ingelheim Investigational Site
city: Kemerovo
country: Russian Federation
facility: 1245.25.70015 Boehringer Ingelheim Investigational Site
city: Kemerovo
country: Russian Federation
facility: 1245.25.70020 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1245.25.70003 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1245.25.70009 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1245.25.70011 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1245.25.70016 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1245.25.70021 Boehringer Ingelheim Investigational Site
city: Moscow
country: Russian Federation
facility: 1245.25.70022 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 1245.25.70014 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 1245.25.70018 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 1245.25.70024 Boehringer Ingelheim Investigational Site
city: Novosibirsk
country: Russian Federation
facility: 1245.25.70028 Boehringer Ingelheim Investigational Site
city: Saint Petersburg
country: Russian Federation
facility: 1245.25.70005 Boehringer Ingelheim Investigational Site
city: Saint Petersburg
country: Russian Federation
facility: 1245.25.70025 Boehringer Ingelheim Investigational Site
city: Saint Petersburg
country: Russian Federation
facility: 1245.25.70026 Boehringer Ingelheim Investigational Site
city: Saint Petersburg
country: Russian Federation
facility: 1245.25.70027 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1245.25.70001 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1245.25.70004 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1245.25.70006 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1245.25.70013 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1245.25.70017 Boehringer Ingelheim Investigational Site
city: St. Petersburg
country: Russian Federation
facility: 1245.25.70023 Boehringer Ingelheim Investigational Site
city: Vsevolozhsk
country: Russian Federation
facility: 1245.25.70002 Boehringer Ingelheim Investigational Site
city: Yaroslavl
country: Russian Federation
facility: 1245.25.70029 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 1245.25.65001 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 1245.25.65003 Boehringer Ingelheim Investigational Site
city: Singapore
country: Singapore
facility: 1245.25.65004 Boehringer Ingelheim Investigational Site
city: Alberton
country: South Africa
facility: 1245.25.76007 Boehringer Ingelheim Investigational Site
city: Bellville
country: South Africa
facility: 1245.25.76002 Boehringer Ingelheim Investigational Site
city: Bloemfontein
country: South Africa
facility: 1245.25.76009 Boehringer Ingelheim Investigational Site
city: Cape Town
country: South Africa
facility: 1245.25.76014 Boehringer Ingelheim Investigational Site
city: Cape Town
country: South Africa
facility: 1245.25.76020 Boehringer Ingelheim Investigational Site
city: Chatsworth Unit 10
country: South Africa
facility: 1245.25.76022 Boehringer Ingelheim Investigational Site
city: Durban
country: South Africa
facility: 1245.25.76013 Boehringer Ingelheim Investigational Site
city: Durban
country: South Africa
facility: 1245.25.76016 Boehringer Ingelheim Investigational Site
city: Durban
country: South Africa
facility: 1245.25.76019 Boehringer Ingelheim Investigational Site
city: Goodwood
country: South Africa
facility: 1245.25.76003 Boehringer Ingelheim Investigational Site
city: Houghton
country: South Africa
facility: 1245.25.76001 Boehringer Ingelheim Investigational Site
city: Kempton Park
country: South Africa
facility: 1245.25.76021 Boehringer Ingelheim Investigational Site
city: Krugersdorp
country: South Africa
facility: 1245.25.76017 Boehringer Ingelheim Investigational Site
city: Newtown
country: South Africa
facility: 1245.25.76004 Boehringer Ingelheim Investigational Site
city: Paarl
country: South Africa
facility: 1245.25.76006 Boehringer Ingelheim Investigational Site
city: Parow
country: South Africa
facility: 1245.25.76005 Boehringer Ingelheim Investigational Site
city: Port Elizabeth
country: South Africa
facility: 1245.25.76018 Boehringer Ingelheim Investigational Site
city: Somerset West
country: South Africa
facility: 1245.25.76015 Boehringer Ingelheim Investigational Site
city: Sydenham
country: South Africa
facility: 1245.25.76012 Boehringer Ingelheim Investigational Site
city: Tongaat
country: South Africa
facility: 1245.25.76008 Boehringer Ingelheim Investigational Site
city: Worcester
country: South Africa
facility: 1245.25.76023 Boehringer Ingelheim Investigational Site
city: Alcorcon (Madrid)
country: Spain
facility: 1245.25.34025 Boehringer Ingelheim Investigational Site
city: Alicante
country: Spain
facility: 1245.25.34048 Boehringer Ingelheim Investigational Site
city: Alzira
country: Spain
facility: 1245.25.34050 Boehringer Ingelheim Investigational Site
city: Avila
country: Spain
facility: 1245.25.34039 Boehringer Ingelheim Investigational Site
city: Badía del Vallès - Barcelona
country: Spain
facility: 1245.25.34040 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 1245.25.34029 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 1245.25.34030 Boehringer Ingelheim Investigational Site
city: Barcelona
country: Spain
facility: 1245.25.34049 Boehringer Ingelheim Investigational Site
city: Granada
country: Spain
facility: 1245.25.34031 Boehringer Ingelheim Investigational Site
city: Leganes (Madrid)
country: Spain
facility: 1245.25.34024 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1245.25.34013 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1245.25.34023 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1245.25.34026 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1245.25.34028 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1245.25.34033 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1245.25.34036 Boehringer Ingelheim Investigational Site
city: Madrid
country: Spain
facility: 1245.25.34038 Boehringer Ingelheim Investigational Site
city: Mahadahonda (Madrid)
country: Spain
facility: 1245.25.34022 Boehringer Ingelheim Investigational Site
city: Palma de Mallorca
country: Spain
facility: 1245.25.34047 Boehringer Ingelheim Investigational Site
city: Sabadell (Barcelona)
country: Spain
facility: 1245.25.34034 Boehringer Ingelheim Investigational Site
city: Salamanca
country: Spain
facility: 1245.25.34027 Boehringer Ingelheim Investigational Site
city: Santa Cruz de Tenerife
country: Spain
facility: 1245.25.34037 Boehringer Ingelheim Investigational Site
city: Segovia
country: Spain
facility: 1245.25.34046 Boehringer Ingelheim Investigational Site
city: Colombo
country: Sri Lanka
facility: 1245.25.94002 Boehringer Ingelheim Investigational Site
city: Kalubowila
country: Sri Lanka
facility: 1245.25.94005 Boehringer Ingelheim Investigational Site
city: Kandy
country: Sri Lanka
facility: 1245.25.94004 Boehringer Ingelheim Investigational Site
city: Kandy
country: Sri Lanka
facility: 1245.25.94006 Boehringer Ingelheim Investigational Site
city: Nugegoda
country: Sri Lanka
facility: 1245.25.94001 Boehringer Ingelheim Investigational Site
city: Ragama
country: Sri Lanka
facility: 1245.25.94003 Boehringer Ingelheim Investigational Site
city: Hualien
country: Taiwan
facility: 1245.25.88022 Boehringer Ingelheim Investigational Site
city: Kaohsiung
country: Taiwan
facility: 1245.25.88010 Boehringer Ingelheim Investigational Site
city: Kaohsiung
country: Taiwan
facility: 1245.25.88019 Boehringer Ingelheim Investigational Site
city: Taichung
country: Taiwan
facility: 1245.25.88009 Boehringer Ingelheim Investigational Site
city: Taichung
country: Taiwan
facility: 1245.25.88020 Boehringer Ingelheim Investigational Site
city: Tainan
country: Taiwan
facility: 1245.25.88018 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1245.25.88015 Boehringer Ingelheim Investigational Site
city: Taipei
country: Taiwan
facility: 1245.25.88016 Boehringer Ingelheim Investigational Site
city: Tamsui, Taipei county
country: Taiwan
facility: 1245.25.88023 Boehringer Ingelheim Investigational Site
city: Taoyuan
country: Taiwan
facility: 1245.25.88017 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 1245.25.66006 Boehringer Ingelheim Investigational Site
city: Bangkok
country: Thailand
facility: 1245.25.66007 Boehringer Ingelheim Investigational Site
city: Chiang Mai
country: Thailand
facility: 1245.25.66009 Boehringer Ingelheim Investigational Site
city: Muang District
country: Thailand
facility: 1245.25.66004 Boehringer Ingelheim Investigational Site
city: Nakhonratchasima
country: Thailand
facility: 1245.25.66010 Boehringer Ingelheim Investigational Site
city: Pathum Tani
country: Thailand
facility: 1245.25.66011 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 1245.25.75009 Boehringer Ingelheim Investigational Site
city: Kharkiv
country: Ukraine
facility: 1245.25.75011 Boehringer Ingelheim Investigational Site
city: Kharkov
country: Ukraine
facility: 1245.25.75001 Boehringer Ingelheim Investigational Site
city: Kharkov
country: Ukraine
facility: 1245.25.75008 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 1245.25.75007 Boehringer Ingelheim Investigational Site
city: Kiev
country: Ukraine
facility: 1245.25.75012 Boehringer Ingelheim Investigational Site
city: Odessa
country: Ukraine
facility: 1245.25.75010 Boehringer Ingelheim Investigational Site
city: Airdrie
country: United Kingdom
facility: 1245.25.44045 Boehringer Ingelheim Investigational Site
city: Ashford
country: United Kingdom
facility: 1245.25.44020 Boehringer Ingelheim Investigational Site
city: Blackpool
country: United Kingdom
facility: 1245.25.44013 Boehringer Ingelheim Investigational Site
city: Bolton
country: United Kingdom
facility: 1245.25.44014 Boehringer Ingelheim Investigational Site
city: Bradford on Avon
country: United Kingdom
facility: 1245.25.44021 Boehringer Ingelheim Investigational Site
city: Dumfries
country: United Kingdom
facility: 1245.25.44002 Boehringer Ingelheim Investigational Site
city: Dundee
country: United Kingdom
facility: 1245.25.44009 Boehringer Ingelheim Investigational Site
city: Edinburgh
country: United Kingdom
facility: 1245.25.44005 Boehringer Ingelheim Investigational Site
city: Fowey
country: United Kingdom
facility: 1245.25.44004 Boehringer Ingelheim Investigational Site
city: Frome
country: United Kingdom
facility: 1245.25.44001 Boehringer Ingelheim Investigational Site
city: Inverness
country: United Kingdom
facility: 1245.25.44003 Boehringer Ingelheim Investigational Site
city: Wishaw
country: United Kingdom
facility: 1245.25.44044 Boehringer Ingelheim Investigational Site
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References:
citation: Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.
citation: Kahl S, Ofstad AP, Zinman B, Wanner C, Schuler E, Sattar N, Inzucchi SE, Roden M. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes Obes Metab. 2022 Jun;24(6):1061-1071. doi: 10.1111/dom.14670. Epub 2022 Mar 8.
citation: Ruggenenti P, Kraus BJ, Inzucchi SE, Zinman B, Hantel S, Mattheus M, von Eynatten M, Remuzzi G, Koitka-Weber A, Wanner C. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine. 2021 Dec 24;43:101240. doi: 10.1016/j.eclinm.2021.101240. eCollection 2022 Jan.
citation: Reifsnider OS, Kansal AR, Wanner C, Pfarr E, Koitka-Weber A, Brand SB, Stargardter M, Wang C, Kuti E, Ustyugova A. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. Am J Kidney Dis. 2022 Jun;79(6):796-806. doi: 10.1053/j.ajkd.2021.09.014. Epub 2021 Nov 6.
citation: Ferreira JP, Inzucchi SE, Mattheus M, Meinicke T, Steubl D, Wanner C, Zinman B. Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022 Jan;24(1):135-141. doi: 10.1111/dom.14559. Epub 2021 Oct 4.
citation: Vaduganathan M, Inzucchi SE, Sattar N, Fitchett DH, Ofstad AP, Brueckmann M, George JT, Verma S, Mattheus M, Wanner C, Zinman B, Butler J. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2021 Dec;23(12):2775-2784. doi: 10.1111/dom.14535. Epub 2021 Oct 7.
citation: Sharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George JT, Hantel S, Desai N, Mentz RJ. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. JACC Heart Fail. 2021 Aug;9(8):568-577. doi: 10.1016/j.jchf.2021.03.003.
citation: Cherney DZI, Dagogo-Jack S, McGuire DK, Cosentino F, Pratley R, Shih WJ, Frederich R, Maldonado M, Liu J, Wang S, Cannon CP; VERTIS CV Investigators. Kidney outcomes using a sustained >/=40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clin Cardiol. 2021 Aug;44(8):1139-1143. doi: 10.1002/clc.23665. Epub 2021 Jun 15.
citation: Ferreira JP, Kraus BJ, Zwiener I, Lauer S, Zinman B, Fitchett DH, Koitka-Weber A, George JT, Ofstad AP, Wanner C, Zannad F. Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc. 2021 Apr 6;10(7):e020053. doi: 10.1161/JAHA.120.020053. Epub 2021 Mar 23.
citation: Ferreira JP, Verma S, Fitchett D, Ofstad AP, Lauer S, Zwiener I, George J, Wanner C, Zinman B, Inzucchi SE. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020 Nov 26;19(1):200. doi: 10.1186/s12933-020-01174-6.
citation: McGuire DK, Zinman B, Inzucchi SE, Wanner C, Fitchett D, Anker SD, Pocock S, Kaspers S, George JT, von Eynatten M, Johansen OE, Jamal W, Mattheus M, Elsasser U, Hantel S, Lund SS. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol. 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2.
citation: Ceriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020 Oct 13;19(1):176. doi: 10.1186/s12933-020-01147-9.
citation: Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE; EMPA-REG OUTCOME Investigators. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2020 Dec;43(12):3007-3015. doi: 10.2337/dc20-1096. Epub 2020 Oct 1.
citation: Levin A, Perkovic V, Wheeler DC, Hantel S, George JT, von Eynatten M, Koitka-Weber A, Wanner C; EMPA-REG OUTCOME Investigators. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial. Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1433-1444. doi: 10.2215/CJN.14901219. Epub 2020 Sep 29.
citation: Waijer SW, Xie D, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, von Eynatten M, Inker LA, Wanner C, Heerspink HJL. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc. 2020 Sep 15;9(18):e016976. doi: 10.1161/JAHA.120.016976. Epub 2020 Sep 6.
citation: Bohm M, Fitchett D, Ofstad AP, Brueckmann M, Kaspers S, George JT, Zwiener I, Zinman B, Wanner C, Marx N, Mancia G, Anker SD, Mahfoud F. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. J Hypertens. 2020 Sep;38(9):1829-1840. doi: 10.1097/HJH.0000000000002492.
citation: Inzucchi SE, Khunti K, Fitchett DH, Wanner C, Mattheus M, George JT, Ofstad AP, Zinman B. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. J Clin Endocrinol Metab. 2020 Sep 1;105(9):3025-35. doi: 10.1210/clinem/dgaa321.
citation: Ferreira JP, Fitchett D, Ofstad AP, Kraus BJ, Wanner C, Zwiener I, Zinman B, Lauer S, George JT, Rossignol P, Zannad F. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. Am J Hypertens. 2020 Dec 31;33(12):1092-1101. doi: 10.1093/ajh/hpaa073.
citation: Perkovic V, Koitka-Weber A, Cooper ME, Schernthaner G, Pfarr E, Woerle HJ, von Eynatten M, Wanner C. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME(R) trial. Nephrol Dial Transplant. 2020 Dec 4;35(12):2103-2111. doi: 10.1093/ndt/gfz179.
citation: Kansal A, Reifsnider OS, Proskorovsky I, Zheng Y, Pfarr E, George JT, Kandaswamy P, Ruffolo A. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med. 2019 Nov;36(11):1494-1502. doi: 10.1111/dme.14076. Epub 2019 Jul 23.
citation: Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.
citation: Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators. Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. J Am Coll Cardiol. 2019 Jun 4;73(21):2780-2782. doi: 10.1016/j.jacc.2019.03.002. Epub 2019 Mar 15. No abstract available.
citation: Januzzi J, Ferreira JP, Bohm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F. Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. No abstract available.
citation: Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.
citation: Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(R) randomised trial. Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19.
citation: Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care. 2018 Apr;24(8 Suppl):S138-S145.
citation: Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.
citation: Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.
citation: Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27.
citation: Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, Mattheus M, Woerle HJ, Broedl UC, Johansen OE, Albers GW, Diener HC; EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke. 2017 May;48(5):1218-1225. doi: 10.1161/STROKEAHA.116.015756. Epub 2017 Apr 6.
citation: Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
citation: Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
citation: Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014 Jun 19;13:102. doi: 10.1186/1475-2840-13-102.